Nilotinib: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
===Better Known as: Tasigna=== | ===Better Known as: Tasigna=== | ||
* Marketed By: Novartis | * Marketed By: Novartis | ||
* Major Indication: Chronic Myelogenous [[Cancer|Leukemia]] | * Major Indication: Chronic Myelogenous [[Cancer|Leukemia]] (CML) | ||
* Drug Class: Receptor Tyrosine Kinase (Especially BCR-Abl) Inhibitor | * Drug Class: Receptor Tyrosine Kinase (Especially BCR-Abl) Inhibitor | ||
* Date of FDA Approval (Expiration): 2007 (2023) | * Date of FDA Approval (Expiration): 2007 (2023) | ||
* Expected Sales in Combination with [[Imatinib]]: $ | * Expected Sales in Combination with [[Imatinib]]: $5 Billion | ||
* Importance: | * Importance: It is a powerful second generation BCR-Abl inhibitor. Recent studies have revealed that Nilotinib is more effective than Gleevec in treating blood [[cancer]], highlighting that Nilotinib might be considered the Gold standard CML treatment in a few years. It is specific for BCR-Abl.<ref>PMID:1672137</ref> | ||
* See [[Pharmaceutical Drugs]] for more information about other drugs and disorders | * See [[Pharmaceutical Drugs]] for more information about other drugs and disorders | ||
